ArticleVeterinary research2011
Characterization of in vivo-acquired resistance to macrolides of Mycoplasma gallisepticum strains isolated from poultry.
Article in Veterinary research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 60 citations in OpenAlex.
- Natural Products AgainstMicroorganisms · 2026Review
- Article
- Biological characterization, sequence type distribution and drug resistance profiling ofFrontiers in veterinary science · 2026Article
- Unraveling Antimicrobial Resistance Dynamics in Mycoplasma gallisepticum: Insights Into Antibiotic and Disinfectant Interactions.Veterinary medicine and science · 2025Article
- Molecular detection of antimicrobial resistance in livestock mycoplasmas: current status and future prospects.Frontiers in veterinary science · 2025Review
- Detection ofArchives of Razi Institute · 2023Article
- The Monitoring ofAntibiotics (Basel, Switzerland) · 2022Article
- Targeted sequencing analysis of Mycoplasma gallisepticum isolates in chicken layer and breeder flocks in Thailand.Scientific reports · 2022Article
- Antibiotic resistance of Mycoplasma Synoviae strains isolated in China from 2016 to 2019.BMC veterinary research · 2022Article
- Pharmacokinetic and Pharmacodynamic integration of tilmicosin againstFrontiers in veterinary science · 2022Article
- Integrating the Human and Animal Sides of Mycoplasmas Resistance to Antimicrobials.Antibiotics (Basel, Switzerland) · 2021Review
- Backyard poultry cases in UK small animal practices: Demographics, health conditions and pharmaceutical prescriptions.The Veterinary record · 2021Article
- The PK/PD Integration and Resistance of Tilmicosin againstPathogens (Basel, Switzerland) · 2020Article
- Allometric analysis of tylosin tartrate pharmacokinetics in growing male turkeys.Journal of veterinary science · 2020Article
- Efficacy data of halogenated phenazine and quinoline agents and an NH125 analogue to veterinary mycoplasmas.BMC veterinary research · 2020Article
- Article
- Evidence for Multidrug Resistance in Nonpathogenic Mycoplasma Species Isolated from South African Poultry.Applied and environmental microbiology · 2018Article
- Antimicrobial Resistance inMicrobiology spectrum · 2018Review
- Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): avian mycoplasmosis (EFSA journal. European Food Safety Authority · 2017Article
- Antimicrobial Resistance in Bacterial Poultry Pathogens: A Review.Frontiers in veterinary science · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The macrolide class of antibiotics, including tylosin and tilmicosin, is widely used in the veterinary field for prophylaxis and treatment of mycoplasmosis. In vitro susceptibility testing of 50 strains of M. gallisepticum isolated in Israel during the period 1997-2010 revealed that acquired resistance to tylosin as well as to tilmicosin was present in 50% of them. Moreover, 72% (13/18) of the strains isolated from clinical samples since 2006 showed acquired resistance to enrofloxacin, tylosin and tilmicosin. Molecular typing of the field isolates, performed by gene-target sequencing (GTS), detected 13 molecular types (I-XIII). Type II was the predominant type prior to 2006 whereas type X, first detected in 2008, is currently prevalent. All ten type X strains were resistant to both fluoroquinolones and macrolides, suggesting selective pressure leading to clonal dissemination of resistance. However, this was not a unique event since resistant strains with other GTS molecular types were also found. Concurrently, the molecular basis for macrolide resistance in M. gallisepticum was identified. Our results revealed a clear-cut correlation between single point mutations A2058G or A2059G in domain V of the gene encoding 23S rRNA (rrnA, MGA_01) and acquired macrolide resistance in M. gallisepticum. Indeed, all isolates with MIC ≥ 0.63 μg/mL to tylosin and with MIC ≥ 1.25 μg/mL to tilmicosin possess one of these mutations, suggesting an essential role in decreased susceptibility of M. gallisepticum to 16-membered macrolides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.